Literature DB >> 20657164

Multidimensional analyses of long-term clinical courses of asthma and chronic obstructive pulmonary disease.

Toru Oga1, Mitsuhiro Tsukino2, Takashi Hajiro3, Akihiko Ikeda4, Hiroshi Koyama5, Michiaki Mishima6, Kazuo Chin7, Koichi Nishimura8.   

Abstract

Asthma and chronic obstructive pulmonary disease (COPD) are chronic respiratory disorders involving obstructive airway defects. There have been many discussions on their similarities and differences. Although airflow limitation expressed as forced expiratory volume in one second (FEV(1)) has been considered to be the main diagnostic assessment in both diseases, it does not reflect the functional impairment imparted to the patients by these diseases. Therefore, multidimensional approaches using multiple measurements in assessing disease control or severity have been recommended, and multiple endpoints in addition to FEV(1) have been set recently in clinical trials so as not to miss the overall effects. In particular, as improving symptoms and health status as well as pulmonary function are important goals in the management of asthma and COPD, some patient-reported measurements such as health-related quality of life or dyspnea should be included. Nonetheless, there have been few reviews on the long-term clinical course comparing asthma and COPD as predicted by measurements other than airflow limitation. Here, we therefore analyzed and compared longitudinal changes in both physiological measurements and patient-reported measurements in asthma and COPD. Although both diseases showed similar long-term progressive airflow limitation similarly despite guideline-based therapies, disease progression was different in asthma and COPD. In asthma, patient-reported assessments of health status, disability and psychological status remained clinically stable over time, in contrast to the significant deterioration of these parameters in COPD. Thus, because a single measurement of airflow limitation is insufficient to monitor these diseases, multidimensional analyses are important not only for disease control but also for understanding disease progression in asthma and COPD.

Entities:  

Mesh:

Year:  2010        PMID: 20657164     DOI: 10.2332/allergolint.10-RA-0184

Source DB:  PubMed          Journal:  Allergol Int        ISSN: 1323-8930            Impact factor:   5.836


  6 in total

1.  Prediction of Pulmonary Function in Patients with Chronic Obstructive Pulmonary Disease: Correlation with Quantitative CT Parameters.

Authors:  Hyun Jung Koo; Sang Min Lee; Joon Beom Seo; Sang Min Lee; Namkug Kim; Sang Young Oh; Jae Seung Lee; Yeon Mok Oh
Journal:  Korean J Radiol       Date:  2019-04       Impact factor: 3.500

2.  Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study.

Authors:  Victoria Federico Paly; Ian Naya; Necdet B Gunsoy; Maurice T Driessen; Nancy Risebrough; Andrew Briggs; Afisi S Ismaila
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-05-03

3.  When to Use Initial Triple Therapy in COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment.

Authors:  Wen-Chien Cheng; Biing-Ru Wu; Wei-Chih Liao; Chih-Yu Chen; Wei-Chun Chen; Te-Chun Hsia; Chih-Yen Tu; Chia-Hung Chen; Wu-Huei Hsu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-12-22

4.  Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression.

Authors:  Craig J Galbán; Meilan K Han; Jennifer L Boes; Komal A Chughtai; Charles R Meyer; Timothy D Johnson; Stefanie Galbán; Alnawaz Rehemtulla; Ella A Kazerooni; Fernando J Martinez; Brian D Ross
Journal:  Nat Med       Date:  2012-10-07       Impact factor: 53.440

Review 5.  Measuring disease activity in COPD: is clinically important deterioration the answer?

Authors:  Dave Singh; Gerard J Criner; Ian Naya; Paul W Jones; Lee Tombs; David A Lipson; MeiLan K Han
Journal:  Respir Res       Date:  2020-06-02

6.  Long-term outcomes following first short-term clinically important deterioration in COPD.

Authors:  Ian P Naya; Lee Tombs; Hana Muellerova; Christopher Compton; Paul W Jones
Journal:  Respir Res       Date:  2018-11-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.